Oxford BioMedica (OTCMKTS:OXBDF) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Oxford BioMedica (OTCMKTS:OXBDF) from a hold rating to a sell rating in a research note released on Wednesday morning, Zacks.com reports.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, HC Wainwright reiterated a buy rating and issued a $14.50 price objective on shares of Oxford BioMedica in a research report on Wednesday, September 4th.

Shares of OTCMKTS:OXBDF traded up $0.16 on Wednesday, hitting $7.21. The company’s stock had a trading volume of 1,235 shares, compared to its average volume of 422. The company has a market capitalization of $473.19 million, a PE ratio of 48.03 and a beta of 0.77. Oxford BioMedica has a 1 year low of $6.20 and a 1 year high of $10.02. The company has a 50-day simple moving average of $6.90 and a 200 day simple moving average of $8.13.

Oxford BioMedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Featured Article: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit